British drugmaker GlaxoSmithKline said its net profit rocketed in the first quarter on a vast exceptional gain following a deal with Swiss peer Novartis.
Earnings after tax surged to £8.089 billion (€11bn) in the three months to the end of March, compared with £668m in the same period a year earlier, GSK said in a results statement.
GSK took an exceptional gain of £9.262bn before tax - or £7.342bn after tax - on the Novartis transaction which completed in the first quarter.
GSK sold its oncology business to Novartis for $16bn, while buying the Swiss group's vaccines division in return.
The pair also formed a joint venture for consumer health products.